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The angiotensin-converting enzyme (ACE) gene DD homo-
zygote has been suggested to be a significant risk factor for
the progression of diabetic nephropathy. We analyzed clinical
parameters and ACE genotype distribution between type 2
diabetic patients at the extremes of renal risk, i.e. an end-stage
renal failure (ESRF) group (n = 103, group 1) who were on
dialysis therapy due to progression of diabetic nephropathy,
and a no progression group (n = 88, group 2) who had main-
tained normal renal function and normoalbuminuria for more
than 15 years. There were no significant differences in age,
sex, body mass index, HbA1c level, or lipid profiles between
the two groups (p > 0.05). Group 1 had a significantly higher
prevalence of hypertension [group 1: 82.5% (85/103) vs. group
2: 50.0% (44/88), p < 0.05] and diabetic retinopathy [group 1:
103/103 (100%) vs. group 2: 28/88 (31.8%), p < 0.05] than
group 2. Daily urinary albumin excretion was also higher in
group 1 than in group 2 [group 1: 2873 ± 2176 mg/day vs. 12
± 7 g/day, p < 0.05]. The frequencies of the DD, ID, and II
genotypes of the ACE gene in group 1 and group 2 were
26.2%, 47.6%, and 26.2%, and 7.9%, 57.9%, and 34.2%,
respectively. The ACE genotype frequencies between the two
groups were significantly different according to a chi-square
test with Bonferroni's correction (p = 0.004). The presence of
the DD genotype increased the risk of ESRF 4.286-fold
compared to the II genotype [odds ratio 4.286, 95% CI 1.60-
11.42, p = 0.005]. The frequency of the D-allele was higher
in both male and female patients in group 1 compared to group
2, but reached statistical significance only in males [male,
group 1: 50.8% vs. group 2: 35.0%, p = 0.018, female, group
1: 48.8% vs. group 2: 39.5%, p = 0.231]. This study, although
limited by sample size, showed that type 2 diabetic ESRF
patients more frequently expressed the DD genotype. These
findings may substantiate the previously noted relationship
between the ACE DD genotype and the progression of diabetic
nephropathy in Korean type 2 diabetic patients.
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INTRODUCTION
Approximately 10 to 40% of diabetic patients
develop diabetic nephropathy. The pathogenesis
of this drastic complication is not clearly under-
stood, but available data suggest that multiple
factors contribute to this complication, such as
hemodynamic alterations, metabolic abnorma-
lities, various growth factors, and genetic factors.
1
Recent publications suggest that genetic predispo-
sition plays a role in the development of diabetic
nephropathy, which clusters within families in
both type 1 and type 2 diabetes mellitus.
2-5
Fur-
thermore, antihypertensive drugs such as ACE in-
hibitors or angiotensin II receptor blockers (ARBs)
have beneficial effects over other classes of antihy-
pertensive drugs in retarding the development
and progression of diabetic nephropathy.6-8 These
findings suggest that genes involved in the renin-
angiotensin system (RAS) are important in the
pathogenesis of diabetic nephropathy. Various
genes, including the angiotensinogen gene, renin
gene, ACE gene, and angiotensin II type 1 re-
ceptor gene, are involved in the RAS. The inser-
tion/deletion (I/D) polymorphism of the ACE
Polymorphism of the ACE Gene in Dialysis Patients:
Overexpression of DD Genotype in Type 2 Diabetic
End-Stage Renal Failure Patients
Hyeong Cheon Park,1 So Rae Choi,1 Beom Seok Kim,2 Tae Hee Lee,1 Byung Seung Kang,1 Kyu Hyun Choi,2
Ho Yung Lee,2 Dae Suk Han,2 and Sung-Kyu Ha1
Division of Nephrology, Department of Internal Medicine, College of Medicine, 1Yongdong Severance Hospital and 2Severance
Hospital, Institute of Kidney Disease, Yonsei University, Seoul, Korea.
Received April 8, 2005
Accepted June 29, 2005
Reprint address: requests to Dr. Sung-Kyu Ha, Department of
Internal Medicine, Yongdong Severance Hospital, Yonsei Univer-
sity College of Medicine, 146-92 Dogok-dong, Gangnam-gu, Seoul,
Korea. Tel: 82-2-2019-3310, Fax: 82-2-3463-3882, E-mail: hask
1951@yumc.yonsei.ac.kr
Hyeong Cheon Park, et al.
Yonsei Med J Vol. 46, No. 6, 2005
gene has been the most extensively studied
among the candidate genes implicated in the de-
velopment and progression of diabetic nephro-
pathy, although conflicting results have been
reported to date.9-11 Differences in the frequency
of genetic polymorphisms of the ACE gene among
different ethnic groups have been implicated as an
explanation for the observed differences.12 High
ACE activity in the DD genotype, compared to the
ID and II genotypes, has been demonstrated not
only in the plasma but also in several tissues, in-
cluding the heart and kidneys.13,14 Some studies
have demonstrated a more progressive decline in
renal function in diabetic patients with the DD
genotype.15 We have recently reported the impor-
tance of the ACE DD genotype in the progression
of diabetic nephropathy on the basis of renal
function impairment in Korean patients with type
2 diabetes.16 An excess of DD homozygotes has
been noted among Caucasian hemodialysis
patients with type 2 diabetes.17 In this context, we
conducted this cross-sectional study to reassess
the association of the ACE gene polymorphism
with ESRF due to diabetic nephropathy by com-
paring two extreme groups of patients with type
2 diabetes.
MATERIALS AND METHODS
Subjects
Type 2 diabetic patients attending the diabetic
and renal clinics at Yongdong Severance Hospital
in Korea from 1985 to 2001 were screened. The
criteria for recruitment were similar to those de-
scribed previously.16 The diagnosis of type 2
diabetes was based on clinical characteristics that
included: 1) no episodes of ketoacidosis; 2) diag-
nosis of diabetes after the age of 40 years using
American Diabetes Association criteria;18 and 3)
treatment by diet alone, or diet combined with
oral hypoglycemic agents, or fasting serum C-pep-
tide values greater than 1.0 ng/mL (0.333 nmol/L)
in patients treated with insulin. Patients with a
diabetes history of more than 15 years, and those
who had normal renal function, defined as a
serum creatinine level less than 1.2 mg/dL (106 μ
mol/L), at the time of diagnosis were recruited for
the study. A total of 191 patients satisfied the
above criteria. The patients were then allocated
into two groups. Group 1 (n = 103) included
patients who had progressed to end-stage renal
failure due to diabetic nephropathy and were on
dialysis. Group 2 (n = 88) consisted of patients who
had normal renal function (serum creatinine less
than 1.2 mg/dL (106 mol/L), normoalbuminuria,μ
and a duration of diabetes of more than 15 years.
The two extreme groups of type 2 diabetic
patients were compared based on various clinical
parameters and on ACE genotype distributions.
Methods
Measurement of biochemical parameters
After 12 hours of overnight fasting, 5 ml of
EDTA-anticoagulated blood samples were drawn
from the patients, and the samples were centri-
fuged within four hours. Buffy coat layers were
refrigerated for DNA extraction at -20 . The BUN,
serum creatinine, total cholesterol, triglycerides,
and HDL-cholesterol were measured from the
separated plasma. Urinary albumin excretion and
creatinine clearance were measured by 24-hour
urine collection, and urinary albumin excretions
were measured by the nephelometric method
(Behring Nephelometer 100, Marburg, Germany).
Total cholesterol was determined with the choles-
terol oxidase method. Triglyceride levels were de-
termined with glycerol 3-phosphate oxidase-pero-
xidase (without glycerol blanks) on the Synchron
CX5 (Beckman Instruments, Brea, CA, USA). LDL
cholesterol was calculated by Friedewald and
Delong's equation. HbA1c was determined with
ion capture.
Determination of ACE genotypes
For the determination of ACE I/D polymor-
phism, genomic DNA was extracted from peri-
pheral blood leukocytes. A 287-bp I/D polymor-
phism in intron 16 of the ACE was examined by
polymerase chain reaction (PCR). PCR was per-
formed according to the method of Tiret et al.,19
with slight modification. The sequences of the
sense and the antisense primers were 5'-CTGGA
GAC-CACTCCCATCCTTTCT-3' and 5'-GATGTG
GC CATCACAT-TCGTC AGAT-3', respectively.
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PCR was performed in a final volume of 20 Lμ
that contained 200 ng of genomic DNA, 0.5 molμ
of each primer, 0.25 mM dNTP, 1.5 mM/L MgCl2,
50 mM/L KCl, 10 mM/L Tris-HCl (PH 8.4), and 1
U Taq DNA polymerase. Amplification was car-
ried out for 35 cycles with steps of denaturation
at 94 for 2 min, annealing at 58 for 15 sec, and
extension at 72 for 30 sec. The PCR products
were subjected to electrophoresis in 1.5% agarose
gels and stained by ethidium bromide for visuali-
zation. To avoid mistyping of the ID genotype as
DD, we added dimethyl sulfoxide to the PCR
reaction mix to enhance the amplification of the
I-allele and repeated the genotyping procedure
with the DD genotype.
Blood pressure and ophthalmological evaluation
Blood pressures were measured by sphygmo-
manometer in the supine position after 10 minutes
of rest, and the mean of two consecutive blood
pressure readings was recorded. Fundoscopic
examination and fluoroscein angiography were
performed by a retinal specialist.
Statistical analysis
Variables with a normal distribution were
tested with Student's t-test. Variables with skewed
distributions (e.g., cholesterol, triglyceride, uri-
nary albumin excretion, BUN, and creatinine)
were logarithmically transformed and then com-
pared with t-tests. Concomitantly, the non-para-
metric Mann-Whitney U tests were used to an-
alyze variables with skewed distribution. The
ACE genotype distributions in the two groups
were analyzed using the Hardy-Weinberg equa-
tion, and differences in ACE genotype frequency
between the two groups were analyzed using a
chi-square test with Bonferroni's correction. The
contribution of ACE I/D polymorphism in rela-
tion to ESRF was explored with a logistic regres-
sion analysis. We calculated the odds ratios of DD
and ID, compared to II. For each odds ratio, we
calculated a 95% confidence interval and p-value.
The level of significance was defined as p<0.05.
RESULTS
Demographic data are shown in Table 1. All
patients were Korean. There were no significant
differences in age, sex ratio, BMI, HbA1c levels, or
lipid profiles between the two groups (p>0.05).
As expected, group 1 (82 patients on hemodialysis
and 21 patients on continuous ambulatory peri-
toneal dialysis) had a significantly higher preval-
ence of hypertension [group 1: 82.5% (85/103) vs.
group 2: 50.0% (44/88), p<0.05] and diabetic
retinopathy [group 1: 103/103 (100%) vs. group 2:
28/88 (31.8%), p<0.05] than group 2 (no progres-
sion group). Statistically, more patients in group
1 were taking ACE inhibitors or ARBs [group 1:
72.3% (75/103) vs. group 2: 48% (42/88), p<0.05],
and daily urinary albumin excretion was also
higher in group 1 than in group 2 [group 1: 2873
± 2176 mg/day vs. 12 ± 7 mg/day, p<0.05]. For
glycemic control, group 1 patients were more
often treated with insulin, whereas oral hypogly-
cemic agents were more often used in group 2
patients (Table 1).
The distribution of ACE genotypes followed the
Hardy-Weinberg equilibrium for the whole group
(χ2 = 0.7468, p = 0.3875). Both the genotype and al-
lele distributions of the ACE I/D polymorphism
of group 1 were significantly different as com-
pared with group 2 (after chi-square test with
Bonferroni's correction, p = 0.004; Table 2) or with
the background Korean population.20 The DD
genotype was over-represented in type 2 diabetic
ESRF patients (group 1), as compared with the
group 2 patients. The odds ratio for ESRF of the
DD genotype compared to the II genotype was
4.286 (95% CI 1.60-11.42, p = 0.005), and the ID
genotype compared to the II genotype was 1.06
(95% CI 0.55-2.04, p = 0.976) (Table 3).
To examine the sex-specific association of the
ACE genotype in type 2 diabetic ESRF patients,
we compared genotype and allele distributions
separately among men and women. Male
patients showed a significant difference in ACE
genotype frequencies between group 1 and
group 2 (chi-square test with Bonferroni's cor-
rection, p = 0.032, Table 4). The frequency of D-
alleles was also higher in group 1 than in group
2 (group 1: 50.8% vs. group 2: 35.0%, p = 0.018,
Table 4). The odds ratio for ESRF in males with
the DD genotype compared to II genotype was
5.06 (95% CI 1.39- 18.36, p = 0.022), and was 1.36
(95% CI 0.57-3.20, p = 0.625, Table 3) for the ID
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compared to the II genotype. However, in
females, the ACE genotype frequency between
group 1 and group 2 was not significantly dif-
ferent after a chi-square test with Bonferroni's
correction (p = 0.096). The frequency of D-alleles
showed a tendency to be higher in group 1 than
in group 2, but was not statistically significant
(group 1: 48.8% vs. group 2: 39.5%, p = 0.231,
Table 4). The odds ratio for ESRF in females with
the DD genotype compared to II genotype was
3.36 (95% CI 0.73-15.31, p = 0.209), and the odds
ratio for the ID genotype compared to the II
genotype was 0.76 (95% CI 0.27-2.09, p = 0.791,
Table 3).
Table 2. ACE Genotype Frequencies between Group 1 (ESRF) and Group 2 (No Progression Group)
Group 1 (n = 103) Group 2 (n = 88)
ACE genotypes
DD* (%) 27/103 (26.2%) 7/88 (7.9%)
I D (%) 49/103 (47.6%) 51/88 (57.9%)
I I (%) 27/103 (26.2%) 30/88 (34.2%)
Allele frequencies
D-allele 103/206 (50.0%) 65/176 (36.9%)
I-allele 103/206 (50.0%) 111/176 (63.1%)
D, Deletion; I, Insertion; ESRF, end stage renal failure.
*p = 0.004 by χ2 test with Bonferroni's correction.
p = 0.01 by t-test.
Table 1. Clinical Characteristics of Group 1 (ESRF) and Group 2 (No Progression Group)
Group 1 Group 2
Number of patients 103 88
Age (yrs) 60.3 ± 10.1 60.1 ± 11.0
Sex (male:female) 1:0.72 1:0.76
Body mass index (kg/m2) 23.0 ± 2.5 23.4 ± 6.9
Duration in years from onset of diabetes to study 17.5 ± 5.7 19.6 ± 3.4
Systolic blood pressure (mmHg) 157 ± 22 139 ± 19
Diastolic blood pressure (mmHg) 92 ± 13 85 ± 11
Hypertension (%)* 85/103 (82.5%) 44/88 (50%)
Retinopathy (%)* 103/103 (100%) 28/88 (31.8%)
Serum creatinine (mg/dL)* 7.3 ± 2.5 0.9 ± 0.1
HbA1c (%) 6.6 ± 1.8 7.0 ± 1.5
Total cholesterol (mg/dL) 202 ± 61 189 ± 34
Triglyceride (mg/dL) 153 ± 77 167 ± 111
HDL-cholesterol (mg/dL) 38 ± 11 40 ± 11
Urine albumin excretion (mg/day)* 2873 ± 2176 12 ± 7
Treatment of diabetes
Insulin 62 (60.2%) 18 (20.4%)
Oral hypoglycemic agents 41 (39.8%) 70 (79.6%)
Data are mean ± SD.
HDL, high density lipoprotein; ESRF, end stage renal failure.
*p<0.05 by t-test.
p<0.05 by chi-square test.
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DISCUSSION
We recently reported that progression of
diabetic nephropathy occurs more rapidly in type
2 diabetic patients who are homozygous for the D
allele.16 In the present study, we investigated the
frequency of I/D polymorphism of the ACE gene
in type 2 diabetic ESRF patients by comparing
type 2 diabetic patients at the extremes of renal
risk. Two major findings, although limited by the
small sample size, of the present study are: 1) the
DD genotype is over-expressed in type 2 diabetic
patients on dialysis (ESRF), and 2) gender-depen-
dent interactions are present between the ACE
gene DD genotype and type 2 diabetic ESRF
patients.
Many of the previous association studies that
focused on the association between ACE gene
polymorphism and the development and progres-
sion of diabetic nephropathy yielded conflicting
results. A meta-analysis performed using data
from 18 studies, which included 4,773 diabetic
patients, reported that the D-allele was signifi-
cantly associated with diabetic nephropathy in a
dominant manner.
21
Two subsequent meta-an-
alyses,22,23 however, found no significant associa-
tion between D-alleles and diabetic nephropathy
among Caucasian patients with type 1 or type 2
diabetes, but did confirm an association between
nephropathy and the ID or DD genotype among
Table 3. Odds Ratios of ACE Genes for End Stage Renal Failure in Type 2 Diabetic Patients
ACE genes Odds ratio p value 95% confidence interval
Total
DD/I I 4.286 0.005 1.60 11.42
I D/I I 1.06 0.976 0.55 2.04
I I 1.0
Male
DD/I I 5.06 0.022 1.39 18.36
I D/I I 1.36 0.625 0.57 3.20
I I 1.0
Female
DD/I I 3.36 0.209 0.73 15.31
I D/I I 0.76 0.791 0.27 2.09
I I 1.0
D, Deletion; I, Insertion.
Table 4. ACE Genotype Frequencies between Male and Female Patients
Male Female
Group 1 (n = 60) Group 2 (n = 50) Group 1 (n = 43) Group 2 (n = 38)
ACE genotypes
DD*, (%) 16/60 (26.6%) 4/50 (8.0%) 11/43 (25.5%) 3/38 (7.9%)
I D (%) 29/60 (48.3%) 27/50 (54.0%) 20/43 (46.5%) 24/38 (63.2%)
I I (%) 15/60 (25.0%) 19/50 (38.0%) 12/43 27.9%) 11/38 (28.9%)
Allele frequencies
D-allele , § 61/120 (50.8%) 35/100 (35.0%) 42/86 (48.8%) 30/76 (39.5%)
I-allele 59/120 (49.2%) 65/100 (65.0%) 44/86 (51.2%) 46/76 (60.5%)
D, Deletion; I, Insertion.
*group 1 vs. group 2 in male (p=0.032), group 1 vs. group 2 in female (p=0.096), by χ2 test.
group 1 vs. group 2 in male (p=0.018),
§
group 1 vs. group 2 in female (p= 0.231), by t-test.
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Japanese type 2 diabetic patients. The results of
meta-analyses are frequently confounded by pub-
lication bias resulting in the less frequent publi-
cation of negative results, as well as differences in
study design, patient selection, and case defini-
tions. Typically, these studies defined diabetic
renal disease as the presence of micro- or macro-
albuminuria, thereby not taking into account that
patients with microalbuminuria do not always
progress to overt proteinuria and ESRF. Some of
the patients might even regress to normoalbu-
minuria,24 which would lead to perplexing results.
Furthermore, the ethnic differences in the fre-
quency of I/D polymorphism may contribute to
the discrepant results of the association studies.
The specific issue of an association of the DD
genotype with the progression of diabetic nephro-
pathy in an Asian population has been addressed
in previous studies.15,16,25 The insertion and dele-
tion allele frequency of the ACE gene in Koreans
is very similar to that of Chinese or Japanese
subjects.20 The study of Yoshida et al.15 that in-
cluded 168 Japanese type 2 diabetic patients fol-
lowed up for 10 years showed that the ACE DD
genotype has a high prognostic value for the pro-
gressive deterioration of renal function. This study
noted a higher frequency of DD homozygotes in
Japanese patients with type 2 diabetes who
showed evidence of progression. Moreover, their
analysis of the time to ESRF indicated that the DD
genotype accelerated the progression to chronic
renal failure in diabetic nephropathy. Our recent
study also reported that DD alleles were associ-
ated with an increased risk for the deterioration
of renal function in diabetes.16 However, such a
relationship has not been shown in the Chinese
population. The study of Wong et al.,25 which
included substantial pre-dialysis patients with
macroalbuminuria in their significant nephro-
pathy group (comparable to group 1 in our
present study), reported that ACE I/D or ATG
M235T polymorphism does not influence the
development and progression of renal disease in
type 2 Chinese diabetic patients. Notably, the
distribution of ACE I/D polymorphisms was
similar between those with or without significant
nephropathy, and the prevalence of the DD
genotype was lower in the significant diabetic
nephropathy group in Wong's study. The authors
suggested that genetic factors other than I/D
polymorphisms might be involved in the pro-
gression of nephropathy. However, Wong's study
might have failed to assess the influence of ACE
gene polymorphism on the progression of diabetic
nephropathy, due to the fact that their case and
control selections were not focused on the pro-
gression of renal disease.
It has been reported that patients who are
homozygous for the D-allele progress more
rapidly to ESRF,26 and Caucasian type 2 diabetic
patients on dialysis therapy have a greater fre-
quency of the DD genotype.27 The risk of ESRF in
Caucasian patients with type 1 diabetes has been
shown to be increased two-fold in patients with
the DD genotype, as compared to patients with
other genotypes. The ACE genotype distribution
in the patient group was not in accordance with
the Hardy-Weinberg equilibrium, due to a signifi-
cant over-representation of the DD genotype. This
resulted in a significant increase in the D-allele
frequency in these cases compared to the con-
trols.28 A recent report has also shown a rapid
progression towards ESRF in individuals with the
DD genotype, particularly in those who also have
the MM genotype for angiotensinogen.29 Yoshida
et al.15 reported a higher frequency of DD homo-
zygotes in Japanese patients with type 2 diabetes
who showed evidence of progression. In the dia-
lyzed cohort, however, an excess of DD homozy-
gotes was not noted. In the present study, we
found a significant difference in the allele distri-
butions between the group of patients on dialysis
(group 1) and the group with no progression
(group 2). The patients on dialysis showed a high
prevalence of the ACE DD genotype and a low
prevalence of the ACE II genotype. The risk of
ESRF in Korean type 2 diabetic patients was
increased 4.286-fold in patients with the ACE DD
genotype as compared to the ACE II genotype
(p=0.005), a result that closely resembled the data
from the previous Japanese study. The risk of
ESRF was increased 1.06-fold in the ACE ID
genotype compared to the ACE II genotype (p=
0.976). Thus, the presence of one D-allele did not
increase the risk of ESRF, but the presence of two
D-alleles increased the risk of ESRF approximately
four-fold, compared to the ACE II genotype.
These findings suggest that the D-allele is a
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genetic risk factor that behaves as a recessive trait,
requiring the presence of two alleles to contribute
to the progression of ESRF. It is plausible that
increased risk for ischemic heart disease30 and the
reported adverse effects of the deletion polymor-
phism of the ACE gene on survival in diabetic
patients with ESRF31 may have contributed to de-
crease prevalence of DD genotype in the Chinese
ESRF patients. However, it has previously been
proposed that patients who are homozygous for
the D-allele progress more rapidly to ESRF. The
observation of an accumulation of the DD geno-
type in the cohort of dialyzed patients would be
consistent with the notion that these individuals
progress more rapidly to ESRF, and that accumu-
lation outweighs loss secondary to the known
increase in mortality.
It has been suggested that association studies
determining genotype-phenotype relationships re-
quire several criteria to enhance study quality,
such as a stringently defined phenotype and a
large sample size.12 We attempted to examine a
cohort of type 2 diabetic patients at the extremes
of renal risk, restricting the study to Korean
diabetic patients to eliminate racial- and disease-
specific differences on the effects of the ACE
genotype.
Gender has been reported to have an impact on
the development and progression of renal insuf-
ficiency.32 The meta-analysis by Neugarten et al.
analyzed the effect of gender on the development
and progression of nondiabetic renal diseases, and
indicated that men with chronic renal disease of
various etiologies show a more rapid decline in
renal function with time than do women.33 It has
been speculated that direct receptor-mediated
effects of sex hormones may determine suscepti-
bility to renal damage.34 The effect of sex on the
development and progression of diabetic nephro-
pathy, however, is still controversial. Several pro-
spective studies have suggested that men were
more likely to develop albuminuria than women,
35,36 but conflicting results indicating that African-
American women were more likely to develop
diabetic nephropathy as a cause of end-stage renal
disease than men,37 were also reported. In the
present study, the subgroup analysis of the allele
distributions between males and females found
gender-dependent interactions between the ACE
gene and type 2 diabetic ESRF patients. In males,
the ACE genotype frequency between the two
groups was significantly different (p=0.032), and
the frequency of D-allele was also higher in group
1 than in group 2 [group 1: 50.8% vs. group 2:
35.0%, p=0.018]. However, in females, the ACE
genotype frequency between the two groups was
not statistically significant (p=0.096), and the
frequency of the D-allele showed a higher inci-
dence in group 1 than in group 2, but was not
statistically significant [group 1: 48.8% vs. group
2: 39.5%, p=0.231]. Logistic regression analysis
also failed to show any significance of the DD
genotype for the progression to ESRF in females.
These results suggest that the female gender may
ameliorate the risk of progression to ESRF in
Korean type 2 diabetic patients with the DD geno-
type. Our observations may have been due to
chance, due to the small sample size or to the
small size of the female patient group compared
to the male group. Furthermore, whether this
finding resulted from possible interactions
between female sex hormones and the ACE ac-
tivity of the RAS, which may counteract the
negative effects of the DD genotype,34,38 is at
present speculative.
In summary, we observed a significant excess of
DD homozygotes and possible gender-dependent
interactions between the ACE gene in type 2 dia-
betic ESRF patients. Although our study is limited
by sample size, these findings may substantiate
the previously observed relationship between the
ACE DD genotype and the progression of diabetic
nephropathy in Korean type 2 diabetic patients.
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